| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 4.89 | 15.6% | 48.4% |
| Total Income | 4.98 | 15.4% | 51.1% |
| Expenditure | 4.91 | 13.1% | 34.8% |
| PBT | 0.07 | 69.8% | 120.8% |
| Net Profit | 0.07 | 69.8% | 120.8% |
| OPM | 0.27% | 2.77pp | 11.61pp |
| NPM | 1.43% | 2.58pp | 11.86pp |
| EPS | 0.25 | 71.9% | 126.0% |
Brawn Biotech Ltd Reports Q3 2025 Results: Revenue from Operations at INR 579.77 Million
14 Nov 2025 · 14 Nov 2025, 05:51 pm
Summary
Brawn Biotech Ltd, a company primarily engaged in the pharmaceuticals business, has reported its financial results for the quarter and half year ended on 30th September 2025. The revenue from operations stands at INR 579.77 Million.
Key Highlights
- 1
Q3 2025 Revenue from Operations: INR 579.77 Million
- 2
The results were reviewed by the Audit committee and then approved by the Board of Directors
- 3
The Statutory Auditors carried out the limited review for the quarter and half year ended 30th September 2025
- 4
The financial results are prepared in compliance with the Companies (Indian Accounting Standards) Rules, 2015
- 5
No separate reportable segments as per Ind-AS 108 dealing with Operating Segments
- 6
The above Standalone Un-audited Financial Results for the quarter and half year ended on 30-09-2025 are available on the company's website
Management Comments
Not Provided
Not Provided
Informational and educational content only. Not investment advice.